Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Plural six-membered hetero rings consisting of one nitrogen and five carbon atoms

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514277000 - Hetero ring is six-membered consisting of one nitrogen and five carbon atoms

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514333000 Additional hetero ring other than the six-membered hetero rings 71
514335000 Chalcogen bonded directly to a ring carbon of the six-membered hetero ring 31
514334000 The six-membered hetero rings are bonded directly to each other 28
Entries
DocumentTitleDate
20090042944Potassium Channel Inhibitors - The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.02-12-2009
20110003857STABILIZED, ANTIMICROBIALLY EFFECTIVE COMPOSITION WITH A CONTENT OF BISPYRIDINIUM ALKANE - An aqueous-based composition which includes a) at least one bispyridinium alkane (for example octenidine) and b) at least one stabilizer selected from antioxidants, complexing agents, reducing agents, UV filters and photoprotective agents, in particular α-tocopherol, and BHT. The composition can also include c) one or more auxiliaries selected from, for example, nonionic surfactants, ethers, solvents and polymers, in particular fatty alcohol alkoxylates and alkoxylated fatty acid monoglycerides. The presence of the stabilizer reduces or prevents the appearance of decomposition products of bispyridinium alkanes and, in the case of the presence of auxiliaries, of decomposition products of the auxiliaries, such as ethers and peroxides.01-06-2011
20080293772SALTS OF PICOTAMIDE - The invention relates to salts of picotamide (N,N′-bis-(3-picolyl)-4-methoxyisophthalamide) with strong acids, to pharmaceutical compositions containing picotamide salts, and to a method of treatment of cardiovascular and related diseases using picotamide salts. Particularly useful are picotamide hydrochloride and picotamide mesylate, preferably on a carbohydrate carrier such as hydroxymethylpropylcellulose.11-27-2008
20130165482PEST CONTROL AGENT - Specific amine derivatives have been found to possess excellent activities as pest control agents.06-27-2013
20110092543Wound And Mucosa Antiseptic Based on Bispyridiniumalkanes - The invention relates to an antimicrobially effective composition which comprises a) 0.001 to 1% by weight of bispyridiniumalkane, b) humectant and c) water. The composition has an osmolality of from 230 to 350 mOsmol/kg and is free from surfactant. It is used as wound and mucosa antiseptic.04-21-2011
20110039892IMINOPYRIDINE DERIVATIVE AND USE THEREOF - The present invention aims to provide a compound having a superior selective α02-17-2011
20100168172HETEROARYL (SUBSTITUTED)ALKYL N-SUBSTITUTED SULFOXIMINES AS INSECTICIDES - N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects.07-01-2010
20090018167Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states - The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiogenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.01-15-2009
20090281144Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors - Bis-quaternary pyridinium-aldoxime salts are disclosed, and their associated polymorphic character, along with their methods of preparation. Such polymorphic salts may then be used for treatment of exposure to cholinesterase inhibitors, such as a phosphorous containing cholinesterase inhibitor type compound.11-12-2009
20100227887PYRIDINE-2-YL CARBOXYLIC ACID AMIDES - The present invention relates to pyridine-2-yl-carboxylic acid amides which act as metabotropic glutamate receptor antagonists. In particular, the present invention relates to pyridine-2-yl-carboxylic acid amides of formula I09-09-2010
200900992342-pyridinylcycloalkylcarboxamide derivatives as fungicides - A compound of general formula (I):04-16-2009
20090030043Potassium Channel Inhibitors - The present invention relates to tetraaryl methyl amine compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.01-29-2009
20090149503NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES - Compounds of formula (I):06-11-2009
20100324093CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.12-23-2010
200900884562-Pyridinylethylcarboxamide derivatives and their use as Fugicides - A compound of general formula (I)04-02-2009
20090209589N-[(PYRIDIN-2-YL) METHOXY] HETROCYCLYL CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FUNGICIDES - A compound of general formula (I):08-20-2009
200900935212, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives - Synthesis of 2,5-bis-diamine-[1,4]benzoquinonic derivatives having the general formula (I), products and intermediates of said synthesis; the synthesis involves the use of p-benzoquinones having the general formula (IX) and diamines having the general formula (XI).04-09-2009
20090209588Novel compounds, their preparation and use - Novel compounds of the general formula (I), in which the variables are as defined in claim 08-20-2009
20090258903Aminoethane Sulfonamide Orexin Receptor Antagonists - The present invention is directed to aminoethane sulfonamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.10-15-2009
20100261758HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS - Compounds of Formula (I) wherein R10-14-2010
20100261757Insecticidal (Heteroarylalky)alkane Thio and Oxo Amine Derivatives - Certain novel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, b, c, T, W, Y R, R10-14-2010
20080214616Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors - The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C09-04-2008
20090076085DEUTERIUM-ENRICHED NICRAVEN - The present application describes deuterium-enriched nicraven, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20100056576Kinase inhibitors and methods of their use - New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.03-04-2010
20100069439MICROORGANISM CONTROL AGENT AND STABILIZING METHOD - Disclosed is a microorganism control agent containing not less than 1% by weight but less than 10% by weight of N,N′-hexamethylenebis(4-carbamoyl-1-decylpyridinium bromide), not less than 35% by weight but less than 60% by weight of at least one alcohol having 2 or 3 carbon atoms, water and an acid.03-18-2010
20100280075PACLITAXEL ENHANCER COMPOUNDS - Disclosed is a compound represented by the Structural Formula (I):11-04-2010
20110152323Histone deacetylase inhibitors and uses thereof - The present invention discloses a group of histone deacetylase inhibitors and use thereof. The histone deacetylase inhibitors are useful in the treatment of malignant tumors and the diseases associated with differentiation and proliferation. The histone deacetylase inhibitors are the compounds represented by the following formula or salts thereof:06-23-2011
20110152322Aminopropenoates as Fungicides - The present invention relates to aminopropenoate derivatives, the process of their preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions.06-23-2011
20080242702Paclitaxel enhancer compound - One embodiment of the present invention is a compound represented by the Structural Formula (I):10-02-2008
20080255197CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS - The present invention relates to compounds that bind to chemokine receptors, and having the formula10-16-2008
20100324092PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS - The present invention relates to a novel class of pyridyl and pyrimidinyl derivatives. The pyridyl and pyrimidinyl compounds can be used to treat cancer. The pyridyl and pyrimidinyl compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the pyridyl and pyrimidinyl derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the pyridyl and pyrimidinyl derivatives vivo.12-23-2010
20100016367BIS-PYRINIDIUM COMPOUNDS - A method of treating, inhibiting, or preventing an infection in a subject is described. The method comprises administering to the subject an effective amount of at least one bis-pyridinium compound. The bis-pyridinium compound comprises two aromatic ring structures. Each of the ring structures comprises a pyridine ring, and the ring structures are linked by a linker group of at least 8 atoms in length, said linker group being attached to the nitrogen atoms of the pyridine rings. At least one substituent on at least one of the ring structures is an alkyl group having at least 2 carbon atoms, and no substituent on either of the ring structures is —OH, —SH or an amine group.01-21-2010
20090076084WOUND AND MUCOUS MEMBRANE DISINFECTANT - Aqueous wound and mucous membrane disinfectant containing a) octenidine dihydrochloride, and b) one or more active ingredients selected from the group ethanol, 1-propanol, 2-propanol, undecylene amidopropyl trimonium methosulfate, 3-(4-chlorophenoxy)-1,2-propanediol and/or sodium hydroxymethylglycinate and c) glycerin and/or 1,2-diols having 3 to 10 carbon atoms, and d) optionally surfactants, emulsifiers, solubilisers, pH regulators, dyestuffs, perfumes and/or thickeners, the agent being free of phenoxyethanol, phenoxypropanol, phenoxyisopropanol and organic acids.03-19-2009
20090030042Amide Addition Reaction - A method of making a compound of formula II01-29-2009
20100280074CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.11-04-2010
20120309791NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS - The present invention relates to novel compounds of formula (II) that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating, or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed12-06-2012
20100093802CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.04-15-2010
20090131480Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia - The invention provides methods for treating and/or preventing cognitive impairments, dementia, or neurodegenerative diseases and disorders (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis) in patients by administering therapeutically effective amounts of an AMPA receptor antagonist (e.g., 1,2-dihydropyridine compounds) and therapeutically effective amounts of nootropics (e.g., cholinesterase inhibitors) to patients. The invention also provides combinations, commercial packages, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists (e.g., 1,2-dihydropyridine compounds) and therapeutically effective amounts nootropics (e.g., cholinesterase inhibitors). The 1,2-dihydropyridine compound may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The cholinesterase inhibitor may be, for example, donepezil.05-21-2009
20110184023THE SALTS OF N-[4-(1-CYANOCYCLOPENTYL)PHENYL]-2-(4-PYRIDYLMETHYL)AMINO-3-PYRIDINECARBO- XAMIDE - The present invention relates to the salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl) amino-3-pyridine carboxamide, especially hydrochloride and mesylate thereof, and the use of said salts in the preparation of an antineoplastic medicament.07-28-2011
20100173942PHOSPHODIESTERASE 4 INHIBITORS - PDE4 inhibition is achieved by novel nitroxide compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formulas I-III:07-08-2010
20100204277Compositions and Methods for Controlling Infestation - The present invention is directed to methods of treating pest infestation by inhibiting metabolic processes of the pest such as for example, processes involved in invertebrate remodelling.08-12-2010
20080227819Method for identifying the agonistic activity of a target compound on a potassium channel - A method for identifying the agonistic activity of a target compound on a potassium channel by a) providing a population of cells expressing a potassium channel and, optionally providing, a protein-based fluorescent-optical voltage sensor, b) if necessary, incubating the cells with a voltage-sensitive fluorescent dye, c) adding the target compound to the reaction batch of a) or b), d) determining a value F09-18-2008
20080221165Use of Octenidine Dihydrochloride in Semisolid Preparations - The invention relates to the use of octenidine dihydrochloride for manufacturing a semisolid pharmaceutical composition for the treatment of wounds, atopic dermatitides, infected eczemas, dermatomycoses, vaginal infections, acne, herpes and/or for controlling multidrug-resistant pathogens, where the composition comprises from 0.005 to 5% by weight octenidine dihydrochloride, and a corresponding composition.09-11-2008
20110275675Antimicrobial Dental Materials - Dental material which contains an antimicrobial active ingredient according to general formula (I),11-10-2011
20110275674Small Molecules Modulator of Epigenetic Regulation and Their Therapeutic Applications - Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.11-10-2011
20110237626COMPOSITIONS FOR HYGIENIC HAND DISINFECTION AND DISINFECTANT HANDWASHING - The invention relates to a disinfectant composition which includes a) one or more 1- or 2-(C09-29-2011
20130150409NOVEL TRPV3 MODULATORS - Disclosed herein are modulators of TRPV3 of formula (I)06-13-2013
20130150410Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic disorders with ion channel modulators. In these methods, the ion channel modulator compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the ion channel modulator compositions and formulations onto the auris interna target areas, or via perfusion into the auris interna structures.06-13-2013
20130184311CRYSTALLINE FORMS OF THE SODIUM SALT OF (4--CYCLOHEXYL)-ACETIC ACID - The present invention relates to novel crystalline forms of (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, sodium and their use in the treatment or prevention of a condition or a disorder associated with DGAT1 activity in animals, particularly humans. It also relates to processes for making such novel crystalline forms.07-18-2013
20110313000CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.12-22-2011
20130190354PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR - The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, one or more surfactants with lubricant properties, one or more dry binders with disintegrant properties, one or more fillers and one or more disintegrants.07-25-2013
20120095051CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES - This invention provides a compound having the structure04-19-2012

Patent applications in class Plural six-membered hetero rings consisting of one nitrogen and five carbon atoms

Patent applications in all subclasses Plural six-membered hetero rings consisting of one nitrogen and five carbon atoms